Debate: Should the dose or duration of anticoagulants for the prevention of venous thrombosis be increased in patients with COVID-19 while we are awaiting the results of clinical trials?
File(s)
Author(s)
Gomez, Keith
Laffan, Mike
Bradbury, Charlotte
Type
Journal Article
Date Issued
2021-02
Date Acceptance
2020-10-26
Citation
British Journal of Haematology, 2021, 192 (3), pp.459-466
ISSN
0007-1048
Publisher
Wiley
Start Page
459
End Page
466
Journal / Book Title
British Journal of Haematology
Volume
192
Issue
3
Copyright Statement
© 2020 Owner. This is the accepted version of the following article: Gomez, K., Laffan, M. and Bradbury, C. (2021), Debate: Should the dose or duration of anticoagulants for the prevention of venous thrombosis be increased in patients with COVID‐19 while we are awaiting the results of clinical trials?. Br J Haematol, which has been published in final form at https://doi.org/10.1111/bjh.17241
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000591916300001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Hematology
anticoagulation
clinical trials
coronavirus disease 2019
thromboprophylaxis
venous thrombosis
CRITICALLY-ILL PATIENTS
THROMBOPROPHYLAXIS
COMPLICATIONS
METAANALYSIS
Publication Status
Published
Date Publish Online
2020-11-25